{"id":16152,"date":"2022-04-13T16:30:47","date_gmt":"2022-04-13T14:30:47","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=16152"},"modified":"2022-04-13T16:30:47","modified_gmt":"2022-04-13T14:30:47","slug":"gsk-annonce-la-conclusion-dun-accord-pour-lacquisition-de-sierra-oncology-momelotinib-dans-la-myelofibrose-avec-anemie-par-gsk","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/gsk-annonce-la-conclusion-dun-accord-pour-lacquisition-de-sierra-oncology-momelotinib-dans-la-myelofibrose-avec-anemie-par-gsk\/","title":{"rendered":"GSK annonce la conclusion d\u2019un accord pour l\u2019acquisition de Sierra Oncology (momelotinib dans la my\u00e9lofibrose avec an\u00e9mie) par GSK."},"content":{"rendered":"<p>Le momelotinib diff\u00e9renci\u00e9 de Sierra Oncology a le potentiel de r\u00e9pondre aux besoins m\u00e9dicaux critiques non satisfaits des patients atteints de my\u00e9lofibrose avec an\u00e9mie. Il compl\u00e8te l&#8217;expertise existante de GSK en h\u00e9matologie avec Sierra Oncology anticipant la soumission r\u00e9glementaire aux \u00c9tats-Unis au second trimestre de cette ann\u00e9e et soumission EU au second trimestre 2022.<\/p>","protected":false},"excerpt":{"rendered":"<p>Le momelotinib diff\u00e9renci\u00e9 de Sierra Oncology a le potentiel de r\u00e9pondre aux besoins m\u00e9dicaux critiques non satisfaits des patients atteints de my\u00e9lofibrose avec an\u00e9mie. Il compl\u00e8te l&#8217;expertise existante de GSK [&hellip;]<\/p>","protected":false},"author":17,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[457],"class_list":["post-16152","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-pascale-raoul"],"aioseo_notices":[],"authors":[{"term_id":457,"user_id":17,"is_guest":0,"slug":"pascale-raoul","display_name":"Pascale Raoul","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/?s=96&d=mm&r=g","first_name":"","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=16152"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16152\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=16152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=16152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=16152"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=16152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}